Integrin VLA-5 and FAK are good targets to improve treatment response in the Philadelphia chromosome positive acute lymphoblastic leukemia

Acute lymphoblastic leukemia bearing the Philadelphia chromosome is amongst the most difficult types of ALL to cure. However, the advent of targeted tyrosine kinase inhibitor (TKI) imatinib has ushered in a new era of treatments that have the potential to be less toxic to patients. Integrins and tyr...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Zhongbo eHu, William B Slayton
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2014-05-01
Subjects:	Philadelphia Chromosome Acute Lymphoblastic Leukemia Bone marrow microenvironment tyrosine kinase inhibitor focal adhesion kinase Integrin α5β1
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00112/full